Close Menu
    Latest Category
    • Finance
    • Tech
    • EU Law
    • Energy
    • About
    • Contact
    EUbusiness.com | EU news, business and politicsEUbusiness.com | EU news, business and politics
    Login
    • EU News
    • Focus
    • Guides
    • Press
    • Jobs
    • Events
    • Directory
    EUbusiness.com | EU news, business and politicsEUbusiness.com | EU news, business and politics
    Home » Forum assesses competitiveness of Europe’s pharmaceutical industry

    Forum assesses competitiveness of Europe’s pharmaceutical industry

    npsBy nps6 October 2008Updated:9 July 2024 focus No Comments4 Mins Read
    — Filed under: Pharmaceuticals
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Europe’s Pharmaceutical Forum has concluded its three-year process and, on 2 October, put forward several recommendations addressing the many challenges facing the pharmaceutical industry, public health interests and national healthcare systems.

    The high-level forum was co-chaired by Vice President of the European Commission Günter Verheugen and Commissioner Androulla Vassiliou, and welcomed health ministers of Member States, MEPs, the Secretary General of the European Free Trade Association and representatives of 10 stakeholder organisations.

    The Pharmaceutical Forum’s initial mandate, set out in 2005, was ‘to discuss the competitiveness of the European pharmaceutical industry and related public health considerations, with a specific focus on information to patients on disease and treatment options, relative effectiveness assessments and pricing and reimbursement of medicinal products’.

    The Forum’s final report addressed specific issues in three major areas: improving access to information on diseases and treatments, identifying (and providing fair access to) the most effective medicines and balancing such access with reward for innovation within the limits of healthcare budgets.

    The report stressed the need to provide citizens with more information in effective communication formats (electronic and non-electronic means), ‘taking account of local traditions, healthcare systems and languages’. While acknowledging that doctors are the most appropriate people to provide information to their patients, the Forum recommended that ‘Member States, the Commission and health actors […] consider new collaborations in the field of information to patients. Such collaborations should respect transparency, disclosure of financial and other support as well as definition of responsibilities.’

    The Forum’s report addressed the need to improve information flow, in terms of both patient access to information and data sharing in research and development. Specifically, it spoke of the need to improve data availability and transferability. The report encouraged Member States and stakeholders to regularly exchange information in order to consolidate scientific evidence at national level, to provide this evidence to pricing and reimbursement authorities, and to inform healthcare professionals and patients on the most effective drugs.

    The exchange of effectiveness data should, according to the report, ‘aim to identify any barriers, whether scientific, technical or legal, that prevent all the parties involved from circulating the information easily’. It adds that: ‘national authorities and companies should also consider ways of having early dialogue during product development to improve the generation of appropriate data as far as possible.’

    Member States were called upon to agree on a clear set of expectations on innovations they consider to be valuable. Communication of these common expectations ‘will give companies a clear direction on healthcare priorities and indications on the evidence needed by authorities, while bringing authorities clarity on the mid- to long-term budget needs,’ according to the report. Companies were urged to ‘deliver the innovative medicines that society needs’ and to cooperate with patient organisations.

    Member State authorities, stakeholders and the Commission were encouraged to ‘strengthen their efforts to ensure access to orphan medicines in all EU Member States,’ and to pursue early dialogue on research and development, improve exchange of ‘knowledge on the scientific assessment of the clinical added value’, establish specific pricing and reimbursement mechanisms and increase awareness of orphan diseases.

    The report concluded that: ‘Member States and the Commission, in cooperation with relevant stakeholders, should within the next two years undertake a first review of progress following the recommendations from the Pharmaceutical Forum in the field of pricing and reimbursement […].Further cooperation and exchange of experiences at EU level is needed.’

    Vice President Verheugen said, ‘The Forum’s recommendations can lead to important savings and permit a better reward for pharmaceutical innovation. I call upon industry and national authorities to help implementing these recommendations to the benefit of the patients and healthcare budget.’

    Pharmaceutical Forum

    Source: Community R&D Information Service (CORDIS)

    Add A Comment
    Leave A Reply Cancel Reply

    You must be logged in to post a comment.

    nps
    • Website

    Related Content

    Black Banx

    The Best Banking Solutions for Digital Nomads in 2025

    Business proposals - Image by Ronald Carreño from Pixabay

    Win more business: why small companies need better proposal tools

    Gaming online casino - Photo by Aidan Howe on Pexels

    A Top Level Comparison: Canada vs. the EU Regulatory Environment for Online Casinos and Gambling

    Investing - Photo by Campaign Creators on Unsplash

    Opportunities for savvy investors in the rental market

    Register your company in Estonia

    Establishing a Company in Estonia: Key Advantages for 2025

    MAGA - Photo by Natilyn Hicks Photography on Unsplash

    Navigating the Tariff Storm: Strategic Imperatives for Global Investors in a Fractured Trade Landscape

    LATEST EU NEWS
    Euro - ECB-Photo by Mika Baumeister on Unsplash

    US Dollar remains steady amid Middle East tensions – Euro currency news daily

    16 June 2025

    Brussels to postpone market risk prudential requirements under Basel III by one more year

    12 June 2025
    Cyberattacks - Photo by Tima Miroshnichenko on Pexels

    EUR 145m calls to boost European cybersecurity for hospitals

    12 June 2025
    Detergents - Photo by Liliana Drew on Pexels

    EU Council and Parliament strike deal for safer detergents

    11 June 2025
    Cybersecurity - Image by Franz Bachinger from Pixabay

    EU adopts blueprint for dealing with European cyber crises

    6 June 2025

    Subscribe to EUbusiness Week

    Get the latest EU news

    CONTACT INFO

    • EUbusiness Ltd 117 High Street, Chesham Buckinghamshire, HP5 1DE United Kingdom
    • +44(0)20 8058 8232
    • service@eubusiness.com

    INFORMATION

    • About Us
    • Advertising
    • Contact Info

    Services

    • Privacy Policy
    • Terms
    • EU News

    SOCIAL MEDIA

    Facebook
    eubusiness.com © EUbusiness Ltd 2025

    Design and developed by : 

    Type above and press Enter to search. Press Esc to cancel.

    Sign In or Register

    Welcome Back!

    Login to your account below.

    Lost password?